About
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 296 million people worldwide.
Patients and caregivers
Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.
Healthcare professionals
Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.
Research & development
Discover how Novartis turns breakthrough science into transformative, high-value treatments.
Environmental, social and governance
Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.
Investors
Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.
News
Information for journalists including press releases, statements, stories, multimedia resources and more.
Careers
Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.
Home
Working together, we can reimagine medicine to improve and extend people’s lives.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
